Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 10/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3168745 | 0.91 | ADORA2A (0.56) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 | |
| SCHEMBL3163394 | 0.85 | ADORA1 (0.51) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 | |
| SCHEMBL3156074 | 0.85 | ADORA2A (0.54) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 | |
| SCHEMBL3155766 | 0.85 | ADORA2A (0.51) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 | |
| SCHEMBL3162625 | 0.85 | ADORA2A (0.51) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 | |
| SCHEMBL2903558 | 0.85 | ADORA2A (0.54) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 | |
| SCHEMBL3165790 | 0.84 | ADORA1 (0.50) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 | |
| SCHEMBL3172454 | 0.84 | ADORA1 (0.54) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 | |
| SCHEMBL3156437 | 0.82 | CYP1A2 (0.50) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 | |
| SCHEMBL3155820 | 0.82 | ADORA2A (0.53) | CYP1A2CYP3A4CLK4ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1465631-A4 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1465631-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003053366-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | CYP1A2 331/4885CYP3A4 480/4885CLK4 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.